Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 116

1.

Mice deficient in inducible nitric oxide synthase are susceptible to experimental autoimmune uveoretinitis.

Silver PB, Tarrant TK, Chan CC, Wiggert B, Caspi RR.

Invest Ophthalmol Vis Sci. 1999 May;40(6):1280-4.

PMID:
10235566
2.

Delayed onset and decreased severity of experimental autoimmune uveoretinitis in mice lacking nitric oxide synthase type 2.

Thillaye-Goldenberg B, Goureau O, Naud MC, de Kozak Y.

J Neuroimmunol. 2000 Oct 2;110(1-2):31-44.

PMID:
11024532
3.

Identification of a new epitope of human IRBP that induces autoimmune uveoretinitis in mice of the H-2b haplotype.

Avichezer D, Silver PB, Chan CC, Wiggert B, Caspi RR.

Invest Ophthalmol Vis Sci. 2000 Jan;41(1):127-31.

PMID:
10634611
4.

IFN-gamma-deficient mice develop experimental autoimmune uveitis in the context of a deviant effector response.

Jones LS, Rizzo LV, Agarwal RK, Tarrant TK, Chan CC, Wiggert B, Caspi RR.

J Immunol. 1997 Jun 15;158(12):5997-6005.

PMID:
9190954
5.

A new model of autoimmune disease. Experimental autoimmune uveoretinitis induced in mice with two different retinal antigens.

Caspi RR, Roberge FG, Chan CC, Wiggert B, Chader GJ, Rozenszajn LA, Lando Z, Nussenblatt RB.

J Immunol. 1988 Mar 1;140(5):1490-5.

PMID:
3346541
6.

Protective effect of the type IV phosphodiesterase inhibitor rolipram in EAU: protection is independent of IL-10-inducing activity.

Xu H, Strassmann G, Chan CC, Rizzo LV, Silver PB, Wiggert B, Caspi RR.

Invest Ophthalmol Vis Sci. 1999 Apr;40(5):942-50.

PMID:
10102291
7.

Differential expression of nitric oxide synthase in experimental uveoretinitis.

Zhang J, Wu LY, Wu GS, Rao NA.

Invest Ophthalmol Vis Sci. 1999 Aug;40(9):1899-905.

PMID:
10440241
8.

Anti-tumor necrosis factor alpha therapy suppresses the induction of experimental autoimmune uveoretinitis in mice by inhibiting antigen priming.

Sartani G, Silver PB, Rizzo LV, Chan CC, Wiggert B, Mastorakos G, Caspi RR.

Invest Ophthalmol Vis Sci. 1996 Oct;37(11):2211-8.

PMID:
8843907
9.

Endogenous IL-12 is required for induction and expression of experimental autoimmune uveitis.

Tarrant TK, Silver PB, Chan CC, Wiggert B, Caspi RR.

J Immunol. 1998 Jul 1;161(1):122-7.

10.
11.

IL-18 not required for IRBP peptide-induced EAU: studies in gene-deficient mice.

Jiang HR, Wei X, Niedbala W, Lumsden L, Liew FY, Forrester JV.

Invest Ophthalmol Vis Sci. 2001 Jan;42(1):177-82.

PMID:
11133864
12.

Suramin treatment suppresses induction of experimental autoimmune uveoretinitis (EAU) in rodents.

Sartani G, Silver PB, Strassmann G, Chan CC, Caspi RR.

Curr Eye Res. 1995 Oct;14(10):887-96.

PMID:
8549154
13.

Residues 1-20 of IRBP and whole IRBP elicit different uveitogenic and immunological responses in interferon gamma deficient mice.

Avichezer D, Chan CC, Silver PB, Wiggert B, Caspi RR.

Exp Eye Res. 2000 Aug;71(2):111-8.

PMID:
10930316
14.
15.
16.

Interphotoreceptor retinoid-binding protein (IRBP)-deficient C57BL/6 mice have enhanced immunological and immunopathogenic responses to IRBP and an altered recognition of IRBP epitopes.

Avichezer D, Liou GI, Chan CC, Lewis GM, Wiggert B, Donoso LA, Nickerson JM, Crawford MA, Caspi RR.

J Autoimmun. 2003 Nov;21(3):185-94.

PMID:
14599843
17.
18.

CCR5-deficient mice develop experimental autoimmune uveoretinitis in the context of a deviant effector response.

Takeuchi A, Usui Y, Takeuchi M, Hattori T, Kezuka T, Suzuki J, Okunuki Y, Iwasaki T, Haino M, Matsushima K, Usui M.

Invest Ophthalmol Vis Sci. 2005 Oct;46(10):3753-60.

PMID:
16186359
19.

Mapping immune responses to mRBP-3 1-16 peptide with altered peptide ligands.

Guyver CJ, Copland DA, Calder CJ, Sette A, Sidney J, Dick AD, Nicholson LB.

Invest Ophthalmol Vis Sci. 2006 May;47(5):2027-35.

PMID:
16639012
20.

Effects of experimental ocular inflammation on ocular immune privilege.

Ohta K, Wiggert B, Taylor AW, Streilein JW.

Invest Ophthalmol Vis Sci. 1999 Aug;40(9):2010-8.

PMID:
10440255

Supplemental Content

Support Center